Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
A third Comirnaty vaccine dose increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain antibody levels (median, 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (me 22-fold), Delta, (median, 43-fold), and Omicron (median, 8-fold) variants, but had less impact on S-reactive T-cell immunity in nursing home residents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 1 vom: 24. Aug., Seite e865-e868 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giménez, Estela [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.08.2022 Date Revised 17.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac223 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338452877 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338452877 | ||
| 003 | DE-627 | ||
| 005 | 20231226000716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac223 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338452877 | ||
| 035 | |a (NLM)35314856 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giménez, Estela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2022 | ||
| 500 | |a Date Revised 17.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a A third Comirnaty vaccine dose increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain antibody levels (median, 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (me 22-fold), Delta, (median, 43-fold), and Omicron (median, 8-fold) variants, but had less impact on S-reactive T-cell immunity in nursing home residents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comirnaty COVID-19 vaccine third dose | |
| 650 | 4 | |a SARS-CoV-2-S T cells | |
| 650 | 4 | |a SARS-CoV-2-S antibodies | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a nursing home residents | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Albert, Eliseo |e verfasserin |4 aut | |
| 700 | 1 | |a Zulaica, Joao |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Rusu, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Alicia Rodríguez |e verfasserin |4 aut | |
| 700 | 1 | |a Burgos, Javier S |e verfasserin |4 aut | |
| 700 | 1 | |a Peiró, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Salas, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Vanaclocha, Hermelinda |e verfasserin |4 aut | |
| 700 | 1 | |a Limón, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Alcaraz, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Payá, José |e verfasserin |4 aut | |
| 700 | 1 | |a Díez-Domingo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Comas, Iñaki |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzáles-Candelas, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Geller, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, David |e verfasserin |4 aut | |
| 700 | 0 | |a Valencian Vaccine Research Program (ProVaVac) Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Burgos, J S |e investigator |4 oth | |
| 700 | 1 | |a Meneu de Guillerna, R |e investigator |4 oth | |
| 700 | 1 | |a Vanaclocha, Luna H |e investigator |4 oth | |
| 700 | 1 | |a Burks, D J |e investigator |4 oth | |
| 700 | 1 | |a Cervantes, A |e investigator |4 oth | |
| 700 | 1 | |a Comas, I |e investigator |4 oth | |
| 700 | 1 | |a Díez-Domingo, J |e investigator |4 oth | |
| 700 | 1 | |a Peiro, S |e investigator |4 oth | |
| 700 | 1 | |a González-Candelas, F |e investigator |4 oth | |
| 700 | 1 | |a Ferrer, Albiach C |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Aguado, I |e investigator |4 oth | |
| 700 | 1 | |a Oliver, Ramírez N |e investigator |4 oth | |
| 700 | 1 | |a Sánchez-Payá, J |e investigator |4 oth | |
| 700 | 1 | |a Vento, Torres M |e investigator |4 oth | |
| 700 | 1 | |a Zapater, Latorre E |e investigator |4 oth | |
| 700 | 1 | |a Navarro, D |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 75(2022), 1 vom: 24. Aug., Seite e865-e868 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:1 |g day:24 |g month:08 |g pages:e865-e868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac223 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 1 |b 24 |c 08 |h e865-e868 | ||